Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Payables (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Payables readings, the most recent being $56.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 47.25% year-over-year to $56.8 million, compared with a TTM value of $56.8 million through Dec 2025, up 47.25%, and an annual FY2025 reading of $56.8 million, up 47.25% over the prior year.
  • Payables hit $56.8 million in Q4 2025 for Apellis Pharmaceuticals, up from $38.6 million in the prior quarter.
  • The five-year high for Payables was $56.8 million in Q4 2025, with the low at $4.2 million in Q1 2021.
  • Median Payables over the past 5 years was $29.5 million (2023), compared with a mean of $28.9 million.
  • The sharpest move saw Payables tumbled 54.97% in 2021, then skyrocketed 203.8% in 2022.
  • Year by year, Payables stood at $16.9 million in 2021, then soared by 120.84% to $37.3 million in 2022, then increased by 0.47% to $37.5 million in 2023, then grew by 2.81% to $38.6 million in 2024, then soared by 47.25% to $56.8 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $56.8 million, $38.6 million, and $54.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.